Neurogene Inc
NGNE17.200USD
-1.480-7.92%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
245.43MMarket Cap
LossP/E TTM
More Details of Neurogene Inc Company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
Ticker SymbolNGNE
Company nameNeurogene Inc
IPO dateMar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
Number of employees107
Security typeOrdinary Share
Fiscal year-endMar 07
Address535 W 24Th Street
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10011
Phone18772375020
Websitehttps://www.neurogene.com/
Ticker SymbolNGNE
IPO dateMar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
12.03%
RTW Investments L.P.
9.55%
Casdin Capital, LLC
9.08%
Redmile Group, LLC
8.95%
EcoR1 Capital, LLC
8.91%
Other
51.49%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
12.03%
RTW Investments L.P.
9.55%
Casdin Capital, LLC
9.08%
Redmile Group, LLC
8.95%
EcoR1 Capital, LLC
8.91%
Other
51.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
39.33%
Hedge Fund
29.05%
Investment Advisor
17.40%
Venture Capital
12.03%
Research Firm
10.35%
Individual Investor
9.23%
Bank and Trust
0.08%
Pension Fund
0.07%
Insurance Company
0.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
207
17.85M
125.13%
-2.21M
2025Q1
216
18.11M
126.54%
-1.93M
2024Q4
211
17.68M
118.99%
+934.89K
2024Q3
193
15.29M
117.57%
+50.95K
2024Q2
185
14.71M
113.65%
+656.15K
2024Q1
190
13.87M
122.85%
+4.51M
2023Q4
186
10.89M
99.88%
+9.09M
2023Q3
208
1.31M
59.57%
-490.20K
2023Q2
215
1.27M
59.11%
-309.84K
2023Q1
219
1.22M
57.26%
-516.47K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Samsara BioCapital, LLC
1.72M
12.04%
--
--
Mar 31, 2025
RTW Investments L.P.
1.35M
9.46%
-1.60K
-0.12%
Mar 31, 2025
Casdin Capital, LLC
1.30M
9.08%
--
--
Mar 31, 2025
Redmile Group, LLC
1.31M
9.17%
-11.70K
-0.89%
Mar 31, 2025
EcoR1 Capital, LLC
1.27M
8.91%
--
--
Mar 31, 2025
McMinn (Rachel L. Ph.D.)
1.25M
8.77%
-71.49K
-5.41%
Apr 16, 2025
Baker Bros. Advisors LP
1.49M
10.42%
+811.75K
+120.36%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
946.32K
6.64%
+55.48K
+6.23%
Mar 31, 2025
TD Securities, Inc.
239.26K
1.68%
+239.26K
--
Mar 31, 2025
The Vanguard Group, Inc.
617.93K
4.33%
+49.92K
+8.79%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
